0000000000040098

AUTHOR

Martina Rossi

showing 6 related works from this author

Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.

2013

ObjectiveOur study purpose was to evaluate morbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies.MethodsWe identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso.ResultsThe median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performe…

Adultmedicine.medical_specialtyGenital Neoplasms Femalemedicine.medical_treatmentYoung AdultRetrospective StudieGermanymedicineHumansPostoperative PeriodMortalityAgedRetrospective StudiesAged 80 and overCervical cancerVaginal cancerHysterectomyGynecological malignanciePelvic exenterationbusiness.industryEndometrial cancerMortality rateGynecological malignanciesObstetrics and GynecologyPerioperativeMiddle AgedVulvar cancermedicine.diseaseSurvival AnalysisPelvic ExenterationSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncologyFemaleSurvival AnalysiMorbidityMorbidity pelvic exenteration gynecological malignanciesbusinessHuman
researchProduct

Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study

2018

Objectives This retrospective, multicentric study investigates quality-of-life issues and emotional distress in gynecological cancer survivors submitted to pelvic exenteration (PE). Methods The Global Health Status scale of European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30; the EORTC QLQ-CX24 (CX24), and EORTC QLQ-OV28 questionnaires were administered at least 12 months from surgery only in women with no evidence of further recurrence after PE. Statistical analysis was performed by the analysis of variance (for repeated measures. Results Ninety-six subjects affected by gynecological malignancies receiving PE were enrolled in the s…

Adultmedicine.medical_specialtyConstipationGenital Neoplasms Femalemedicine.medical_treatmentHealth StatusUrinary Diversion03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesmedicineBody ImageHumansAgedRetrospective StudiesGynecology030219 obstetrics & reproductive medicinePelvic exenterationbusiness.industryHazard ratioColostomyRepeated measures designObstetrics and GynecologyRetrospective cohort studyQuality of life Pelvic exenteration Gynecological cancerVulvar cancerMiddle Agedmedicine.diseasePelvic ExenterationOncology030220 oncology & carcinogenesisGynecological cancerQuality of LifeFemalemedicine.symptombusiness
researchProduct

Survival after curative pelvic exenteration for primary or recurrent cervical cancer a retrospective multicentric study of 167 patients

2014

ObjectiveEvaluate the survival of patients who underwent pelvic exenteration (PE) with curative intent for primary persistent or recurrent cervical cancer.MethodsWe retrospectively investigated 167 consecutive patients, referred to the gynecological oncology units of 4 centers in Germany or Italy, who underwent PE. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until last follow-up or death.ResultsThe median age was 51 years. Twenty-seven patients (16.2%) underwent PE owing to advanced primary tumors (group A), 34 patients (20.4%) underwent PE owing to persistent cancer after chemothe…

OncologyUterine Cervical NeoplasmSurvivalmedicine.medical_treatmentUterine Cervical NeoplasmsRetrospective StudieLymph nodeCervical cancerAged 80 and overMedicine (all)Obstetrics and GynecologyMiddle AgedPrognosisCombined Modality TherapySurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisCarcinoma Squamous CellAdenocarcinomaFemaleHumanAdultmedicine.medical_specialtyPrognosiAdenocarcinomaFollow-Up StudieYoung AdultInternal medicinemedicineCarcinomaHumansSurvival pelvic exenteration primary recurrent cervical cancerSurvival rateRetrospective StudiesAgedNeoplasm StagingPelvic exenterationbusiness.industryCancerRetrospective cohort studyLymphatic Metastasimedicine.diseaseSurgeryPelvic ExenterationSettore MED/40 - GINECOLOGIA E OSTETRICIACervical cancerNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified

2014

Peripheral T-cell lymphomas not otherwise specified (PTCLs/NOS) are rare and aggressive tumours whose molecular pathogenesis and diagnosis are still challenging. The microRNA (miRNA) profile of 23 PTCLs/NOS was generated and compared with that of normal T-lymphocytes (CD4+, CD8+, naive, activated). The differentially expressed miRNA signature was compared with the gene expression profile (GEP) of the same neoplasms. The obtained gene patterns were tested in an independent cohort of PTCLs/NOS. The miRNA profile of PTCLs/NOS then was compared with that of 10 angioimmunoblastic T-cell lymphomas (AITLs), 6 anaplastic large-cell lymphomas (ALCLs)/ALK+ and 6 ALCLs/ALK - . Differentially expressed…

Female; Gene Expression Profiling; Humans; Lymphoma T-Cell Peripheral; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; RNA Neoplasm; Gene Expression Regulation Neoplastic; Oncology; Hematology; Medicine (all)Malemedicine.medical_specialtyPathologyPeripheral T-cell lymphoma not otherwise specifiedBiologyhemic and lymphatic diseasesInternal medicinemicroRNAmedicineHumansRNA NeoplasmOligonucleotide Array Sequence AnalysisRegulation of gene expressionHematologymicroRNA; PTCLs/NOS; GEPOligonucleotide Array Sequence AnalysiGene Expression ProfilingMedicine (all)Not Otherwise SpecifiedLymphoma T-Cell PeripheralMicroRNAHematologymedicine.diseaseGEPLymphomaGene expression profilingGene Expression Regulation NeoplasticMicroRNAsOncologyPTCLs/NOSOriginal ArticleFemaleCD8Human
researchProduct

Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.

2014

ObjectiveThe aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.MethodsWe defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.ResultsThe median age was 66 years. A total of 42.9% of the patients had major complications, and a compl…

Pelvic Neoplasmmedicine.medical_specialtySurvivalPrognosimedicine.medical_treatmentendometrial adenocarcinomaGynecologic oncologyAdenocarcinomaFollow-Up StudieRetrospective StudiemedicineHumansEndometrial NeoplasmPelvic NeoplasmsSurvival rateAgedNeoplasm StagingPelvic NeoplasmsRetrospective StudiesAged 80 and overPelvic exenteration recurrent endometrial adenocarcinomaPelvic exenterationbusiness.industryMedicine (all)Endometrial cancerGeneral surgeryObstetrics and GynecologyRecurrent endometrial cancerRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseasePrognosisSurgeryEndometrial Neoplasmspelvic exenterationSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyCohortFemaleMorbidityNeoplasm Recurrence LocalbusinessHumanFollow-Up Studies
researchProduct

The 4MOST Survey of Dwarf Galaxies and their Stellar Streams (4DWARFS)

2023

The present-day Milky Way is the result of a long history of mergers and interactions with smaller galaxies. The 4DWARFS survey will target the dwarf galaxies and stellar streams in the 4MOST footprint, and unveil their chrono-chemo-kinematical properties. The survey will provide radial velocities, chemical abundances and stellar ages for 140 000 stars, and thus increase the number of stars with detailed information in such systems by several orders of magnitude. 4DWARFS will provide a new, deeper view of the Milky Way environment, shedding light on the first stars, chemical evolution, dark matter halos, and hierarchical galaxy formation down to the smallest scales.

Astronomia Observacions
researchProduct